HCP • Aprotinin

Aprotinin

Blood loss requiring transfusion in cardiac surgery remains a risk, despite the use of blood-sparing agents and blood management techniques.¹

Aprotinin is indicated for prophylactic use to reduce blood loss and blood transfusion in adult patients at high risk of major blood loss undergoing isolated cardiopulmonary bypass graft surgery (CABG).(i.e. coronary artery bypass graft surgery that is not combined with other cardiovascular surgery).²Aprotinin should only be used after careful consideration of the benefits and risks, and the consideration that alternative treatments are available.²

Blood loss and transfusions remain a significant risk in cardiac surgery^1,3,4

Aprotinin use and experience videos

Please click here to listen to Professor Jan van der Linden talk about Aprotinin in patients on dual antiplatelet inhibitors undergoing acute CABG

Please click here to access videos and articles on aprotinin use and experience

Aprotinin 10,000 KIU/ml Injection BP

Click here to view the Summary of Product Characteristics

Which patients undergoing isolated CABG are at high risk of transfusion?

About aprotinin

Aprotinin use and monitoring

References

Stevens LM et al. Major transfusions remain frequent despite the generalized use of tranexamic acid: an audit of 3322 patients undergoing cardiac surgery. Transfusion 2016;56:1857-65.
Aprotinin 10,000 KIU/ml Injection BP Summary of Product Characteristics. Available from: https://www.medicines.org.uk/emc/product/2472/smpc.
Mehran R et al. Standardized Bleeding Definitions for Cardiovascular Clinical Trial. A Consensus Report From the Bleeding Academic Research Consortium. Circulation 2011;123:2736-2747.
Gombotz H et al. The second Austrian benchmark study for blood use in elective surgery: results and practice change. Transfusion 2014;54:2646-57.